Adult Dosing

Hereditary angioedema

• 30 mg SC over 30 seconds in abdominal area; may repeat after 6 hrs if inadequate response or if symptoms recur
• Max: 90 mg/24 hours

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Treatment of acute attacks of hereditary angioedema in adults

• Hypersensitivity to any of the ingredients of the products

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

• If airway obstruction due to acute laryngeal hereditary angioedema attack occurs, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with icatibant

Cautions: Use cautiously in

• Acute coronary ischemia
• Unstable angina pectoris
• Stroke

Pregnancy Category:C

Breastfeeding: Safety unknown; excreted ion milk of lactating rat. As many drugs are excreted in human milk manufacturer advise caution.

• CNS: Dizziness
• LOCAL: Injection site reaction
• MISC: Pyrexia, fever
• LABTEST: Transaminase increased

• Adrenergic beta-antagonist; inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of hereditary angioedema
• Metabolized by proteolytic enzymes
• Renally excreted (10% unchanged)
• Half-life: 1.4+/-0.4 hrs

US Trade Name(s)

• Firazyr

US Availability

Firazyr

• INJ: 30 mg/3mL prefilled syringe

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Firazyr

UK Availability

Firazyr

• INJ: 30 mg/3mL prefilled syringe

Australian Trade Name(s)

• Firazyr

Australian Availability

Firazyr

• INJ: 30 mg/3mL prefilled syringe

Immunologic

Immunomodulators

Bradykinin B2 Receptor Antagonists